Featured Research

from universities, journals, and other organizations

More complete picture of kidney cancer: Cancer subtypes distinguished and promising new drug targets suggested

Date:
January 2, 2012
Source:
Van Andel Research Institute
Summary:
Scientists are providing a foundation for a more complete understanding of distinct kidney cancer subtypes, which could pave the way for better treatments.

wo recent studies by Van Andel Research Institute scientists are providing a foundation for a more complete understanding of distinct kidney cancer subtypes, which could pave the way for better treatments.

In a study published in Cancer Cell led by Kyle Furge, Ph.D. and Aikseng Ooi, Ph.D., researchers provide a more complete understanding of the biology of Type 2 papillary renal cell carcinoma (PRCC2), an aggressive type of kidney cancer with no effective treatment, which lays the foundation for the development of effective treatment strategies.

Despite obvious morphological, genetic, and clinical differences, hereditary PRCC2 is thought to share similar pathway deregulation due to genetic mutation with its counterpart, clear cell renal cell carcinoma (CCRCC), a subtype that accounts for 75% of all kidney cancers and that, unlike PRCC2, responds favorably to drugs targeting vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate blood vessel formation.

The study, which included international collaboration with researchers from the National Cancer Centre Singapore, Génétique Oncologique EPFE-INSERM U753 and Faculté de Médecine Paris-Sud, Le Kremlin-Bicêtre and Institut de Cancérologie Gustave Roussy, Michigan State University, Northwestern Memorial Hospital, Cleveland Clinic, Singapore General Hospital, and The Wistar Institute, identified deregulation of the KEAP1-NRF2 signaling pathway as a factor that distinguishes PRCC2 from CCRCC, but links both hereditary and sporadic PRCC2.

In another study published in Cancer Research, led by Yan Ding, Ph.D., and Bin Tean Teh, Ph.D. and carried out in collaboration with the National Cancer Centre Singapore, researchers integrated gene expression profiling and RNAi screening data to identify genes involved in CCRCC development and progression.

In recent years, several molecularly targeted therapies such as sunitinib, sorafenib, and pazopanib, which target the receptor tyrosine kinases of VEGF have been approved for CCRCC. Although these therapies significantly extend overall survival, nearly all patients with advanced CCRCC eventually succumb to the disease.

Gene set enrichment analysis indicated that cell-cycle-related genes, in particular PLK1, were associated with disease aggressiveness. Further, the association of PLK1 in both disease aggression and in vitro growth prompted researchers to examine the effects of a small-molecule inhibitor in CCRCC cell lines. Their findings highlight PLK1 as a promising potential therapeutic target for CCRCC.


Story Source:

The above story is based on materials provided by Van Andel Research Institute. Note: Materials may be edited for content and length.


Cite This Page:

Van Andel Research Institute. "More complete picture of kidney cancer: Cancer subtypes distinguished and promising new drug targets suggested." ScienceDaily. ScienceDaily, 2 January 2012. <www.sciencedaily.com/releases/2011/12/111229203003.htm>.
Van Andel Research Institute. (2012, January 2). More complete picture of kidney cancer: Cancer subtypes distinguished and promising new drug targets suggested. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2011/12/111229203003.htm
Van Andel Research Institute. "More complete picture of kidney cancer: Cancer subtypes distinguished and promising new drug targets suggested." ScienceDaily. www.sciencedaily.com/releases/2011/12/111229203003.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) — Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) — At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) — Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:  

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile iPhone Android Web
      Follow Facebook Twitter Google+
      Subscribe RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins